Eswatini has become the first African nation to begin administering a groundbreaking twice yearly HIV prevention injection, offering new hope in the continent’s ongoing fight against the virus. The preventive drug, lenacapavir, has demonstrated near‑total protection in clinical studies and is being distributed through global health partnerships.
Developed by international pharmaceutical partners and scaled for broader public health use, the twice‑yearly regimen is designed to protect individuals at high risk of HIV infection, a crucial development for regions with persistently high prevalence. Eswatini, which has one of the highest HIV incidence rates globally, initiated the rollout targeting thousands of vulnerable individuals.
Health experts highlight the significance of this intervention, noting that it can markedly reduce new infections and help accelerate progress toward epidemic control. By making preventive treatment more accessible and less frequent, public health systems are better positioned to reach underserved populations.
The initiative is supported by international aid frameworks including PEPFAR and the Global Fund, aligning with broader objectives to expand access to innovative HIV prevention tools across multiple African countries. This multifaceted collaboration underscores the power of partnerships in addressing major health challenges. Early implementation in Eswatini is expected to inform subsequent rollouts in other high‑burden settings, aiding policymakers and health planners in optimizing prevention strategies for sustained impact.